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Background: Sports-related injuries, such as sprains and strains, commonly occur during 
exercise and athletic events. Current therapy includes nonsteroidal anti-inflammatory drugs 
(NSAIDs), which have a high incidence of upper gastrointestinal side effects. The present 
study assessed the efficacy and safety of the diclofenac epolamine topical patch (DETP, 1.3%), 
a topical NSAID for the treatment of acute minor sprains and strains.
Methods: This multicenter, randomized, placebo-controlled clinical study enrolled adult patients 
(n = 134) with acute ankle pain (due to a minor sprain) occurring less than 48 hours prior to 
entering the study. Patients were treated with either the DETP or a placebo topical patch daily 
for seven days. Pain intensity was evaluated during the first six hours after application of the 
patch, and on treatment days 1, 2, 3, and 7.
Results: Patients treated with the DETP experienced a significantly greater reduction in pain 
associated with their ankle injury compared with placebo, beginning four hours after the first 
patch application (P = 0.02). The DETP was well tolerated and was comparable with placebo 
in terms of safety.
Conclusion: Overall, the results of this study demonstrate that the DETP is an effective   analgesic 
for local treatment of pain in mild acute ankle sprain.
Keywords: soft tissue injury, acute pain, visual analog scale, efficacy, tolerability
Introduction
Sports and other exercise-related activities are a major cause of soft tissue and joint 
injuries, resulting in sprains, strains, and contusions. The ankle is frequently   traumatized 
during sports activities, which account for an estimated 20% of all sports-related 
injuries.1 Nonsurgical treatment of ankle sprains is predicated on prevention of fur-
ther injury, reduction of inflammation, and management of pain.1,2 Traditional oral 
  nonsteroidal anti-inflammatory drugs (NSAIDs) are used to provide analgesia and 
relief from inflammation in patients with acute ankle sprain. However, use of these 
drugs can lead to adverse reactions associated with the upper gastrointestinal tract, 
and renal, cardiovascular, and respiratory systems, mainly by reduction of systemic 
prostaglandin production through direct inhibition of cyclooxygenase enzymes.3
In contrast, topical NSAID preparations permit direct application of drug at the site 
of pain. Direct application results in continuous and localized drug delivery to the pain 
site, while minimizing systemic levels of drug (0.2% to 8% of the oral equivalent), 
thereby reducing the local inflammatory reaction while ostensibly avoiding systemic 
adverse events.4 The diclofenac epolamine topical patch (DETP) is a topical NSAID 
patch with demonstrated analgesic activity.5 Prior studies have shown that topical Journal of Pain Research 2011:4 submit your manuscript | www.dovepress.com
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diclofenac can be transported across the skin into the injured 
site, maintaining measurable levels of the drug in synovial 
fluid, while providing a constant plasma level of diclofenac 
for up to 12 hours.6,7
Because the efficacy of the DETP has been demon-
strated in patients treated for minor sports injuries in prior 
studies,8–10 this clinical trial was performed to establish its 
efficacy using a more rigorous methodology. The aim of 
this placebo-controlled clinical study was to demonstrate 
the efficacy and tolerability of the DETP applied once per 
day for seven days in the treatment of minor acute ankle 
sprain. Partial results of this study have been published 
previously in French.10
Methods
This Phase III, multicenter, double-blind, randomized, 
parallel-group, placebo-controlled trial, assessed the efficacy 
and tolerability of the DETP in the treatment of minor ankle 
sprain. The study was performed at 19 French health centers 
and included 24 physician investigators. The study protocol 
was approved by the French Ethical Committee, and was 
conducted in accordance with the Declaration of Helsinki 
guidelines.
study population
Male and female patients, aged 18–65 years, who sustained 
an ankle sprain ,48 hours before study entry and had a 
pain score $50 mm on a 100 mm visual analog scale were 
included in this study if the injury justified use of a seven-day 
NSAID topical treatment. Patients were excluded from the 
study if the ankle sprain required orthopedic or surgical 
treatment, the sprain had been treated prior to study entry, 
they had been treated for other sprains within 1 week of the 
study, or if they had a history of recurrent sprains. Female 
patients who were pregnant, lactating, or of childbearing 
potential were excluded from this study. In addition, patients 
were excluded if they had: an allergy to aspirin, NSAIDs, 
or the excipients in the DETP; a history of skin allergy; or 
an open skin lesion within the injured area (eg, eczema, 
psoriasis). Finally, patients being treated by physiotherapy 
or an alternative medicine (eg, acupuncture, mesotherapy, 
homeopathy) or who had received oral or parenteral treat-
ment with corticosteroids, NSAIDs, or aspirin seven days 
prior to study entry, or had received any analgesic within 
six hours of patient recruitment were also excluded. The 
study was discussed with each of the prospective patients, 
and those wishing to participate signed an informed consent 
form detailing the entire study.
study design
After signing an informed consent, each study patient was 
randomly assigned, in blocks of four and in increasing order, 
a study number corresponding to the preassigned number on a 
packet of blinded test articles (ie, the DETP or placebo patch). 
All patients randomized to the active treatment received 
two boxes, each box containing five DETPs, sufficient for 
a seven-day treatment, with a surplus of three patches. The 
DETP contained diclofenac epolamine 1.3% in a patch 
measuring 10 × 14 cm. Patients who were randomized to the 
placebo group received two boxes, each containing five pla-
cebo patches. Placebo patches were identical in appearance 
and used the same formula as the active patch, without the 
active ingredient, diclofenac epolamine. Patients in both the 
DETP and placebo groups applied a single daily patch to 
the site of injury in the morning, for seven days. The patch 
was maintained by an elastic compression net bandage, and 
changed daily.
The application of ice or protective wrap was allowed in 
both groups and recorded. If necessary, the intake of para-
cetamol was authorized as a rescue medication three hours 
after the first application of a patch; the consumption in both 
groups was recorded. Paracetamol 2 g/day was allowed as 
rescue medication.
Efficacy and safety variables
The duration of treatment was seven days. The primary 
efficacy variable was spontaneous pain (pain on active 
  mobilization), which was assessed by the patient on a 
100 mm Huskisson-type visual analog scale ranging from 
0 = no pain to 100 = severe pain. Spontaneous pain, derived 
from the patient diary, was evaluated at the following times: 
on day 0 at the first six hours after application of the initial 
patch and at 8 pm, on days 1 and 2 at 8 am, 12 pm, and 8 pm, 
and on day 3 at 8 am. At the end of treatment, patients were 
considered “improved” and therapy efficient if the reduction 
in visual analog scale value between entry into the study and 
study termination was $20 mm or if the percentage change 
from baseline in visual analog scale value was $30%. 
An approximately 30% improvement in pain score has been 
considered to be a clinically important difference in treating 
acute pain.11
Secondary efficacy variables included an evaluation of 
the analgesic effect, an assessment of the anti-inflammatory 
effect, and a patient assessment of treatment efficacy. The 
analgesic effect was assessed using the following four 
  parameters: pain at rest according to a four-point verbal 
scale of 0 = no pain, 1 = slight pain, 2 = medium pain, and Journal of Pain Research 2011:4 submit your manuscript | www.dovepress.com
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3 = severe pain; pain on passive stretch and pain on pressure 
(external lateral ligament, front and medium fascicle) accord-
ing to the same pain at rest scale; and possibility of single foot 
leaning on the affected foot according to a three-point scale of 
0 = hold possible without any pain, 1 = hold possible but pain-
ful, and 2 = hold impossible. The anti-inflammatory effect 
was determined by assessing periarticular edema/  swelling, 
which was evaluated by measuring, in mm, the difference 
in circumference between the healthy and impaired ankle, 
using a measuring tape.
The safety measurements included an assessment of 
tolerability by the patient and physician, and a recording of 
adverse events. Each patient who completed the protocol 
was exposed continuously to one patch applied to the painful 
area, with patch renewal once daily for a period of one week. 
A global tolerability assessment was done on day 3 and day 7 
by both the patient and physician. The assessments were 
conducted using a four-point verbal scale, where “none” indi-
cated little tolerability and “excellent” indicated the highest 
levels of tolerability. The patient and physician assessments 
on general tolerability were reported at the end of treatment 
on a four-point scale of excellent, good, fair, and bad.
statistical analysis
All patients who used a study patch were to be included in 
the intent-to-treat analysis. Patients who stopped treatment 
for reasons of “failure”, “worsening”, “healing”, or “disap-
pearance of symptoms” were part of the efficacy analysis, 
with data from the last observation carried forward.
Demographic and baseline characteristics were evaluated 
using Bonferroni’s analysis. The measured parameter visual 
analog scale at the study visits was analyzed by a two-way 
analysis of variance (ANOVA) with factors for treatment 
group and time, and an ANOVA with one factor (time) 
within the groups. Edema, a secondary efficacy variable, 
was analyzed similarly. Categorical variables (ie, single foot 
leaning; pain on pressure, at rest, or on passive stretch; and 
assessments by patient and physician on efficacy and toler-
ability) were analyzed using the Mantel-Haenszel chi-square 
or Fisher’s exact test.
Mean VAS scores were summarized at each patch applica-
tion using a last observation carried forward (LOCF) method 
for imputing missing data. This procedure assumes that the 
subject’s response would have been constant from the last 
observation to the next, or to the end of the trial. In general, 
this is thought to be a highly conservative approach that may 
underestimate therapeutic benefits in a longitudinal study, 
such as this one.
Safety analyses included all patients enrolled in the study, 
and compared the number of patients with specific adverse 
events, total adverse events, and dropout due to treatment 
intolerability between groups.
Results
A total of 134 patients were enrolled in the study by 
24   investigators; 68 patients were randomized to the DETP 
group and 66 patients to the placebo group. All patients were 
included in the analysis of efficacy and safety (intent-to-
treat analysis). A total of 127 patients completed the study 
as planned; seven patients withdrew from the study before 
completion. These withdrawals were for pruritus, protocol 
violation, edema, or lack of efficacy.
The mean age was 33.3 years in the DETP group and 
29.7 years in the placebo group (Table 1). Women in the pla-
cebo group were slightly younger than women in the DETP 
group (P = 0.1), with a lower body mass index (23.6 kg/
m2 DETP versus 21.1 kg/m2 placebo, P = 0.05). A specific 
analysis that adjusted for BMI was performed and showed 
that there were no statistically significant differences between 
the treatment groups related to BMI. There were no differ-
ences between groups for application of ice by the patients 
before enrollment. In addition, no significant differences were 
found in initial measurements of pain or periarticular edema 
between the two groups.
Efficacy
Patients in both treatment groups demonstrated a promi-
nent decrease in mean visual analog scale values over time. 
  However, in the DETP group the decrease in visual analog 
scale score from 66.9 on day 0 to 10.5 on day 7 was signifi-
cantly greater compared with that in the placebo group, which 
decreased from 70.0 on day 0 to 18.4 on day 7 (P = 0.0008). 
Additional analyses revealed that the mean decrease in visual 
analog score measured four hours after the first application 
was two-fold greater for the DETP patients than for those 
given placebo (P = 0.02). The difference in relative change 
was significantly greater for the DETP group at each time 
point, with the exception of day 1 at the 8 am time point, as 
shown by the median change from baseline (see Figure 1).
The success/failure analysis, with success defined as a 
visual analog score reduction of $20 mm between the day 0 
consultation and the last known value, demonstrated that the 
rate of success was significantly higher in the DETP group 
from four hours after the first application, and remained sig-
nificant for six of the 10 measures until day 2 at the 8 pm time 
point. When success/failure was based on change in visual Journal of Pain Research 2011:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
50
Lionberger et al
Table 1 Baseline characteristics of patients in both groups
Characteristic DETP 
(n = 68)
Placebo 
(n = 66)
P valuea
Age, mean (sD) 33.3 (13.9) 29.7 (11.6) 0.1
gender: male/female  33/35 39/27 0.2
Weight: mean (sD)
  Males  75.4 (11.0) 77.7 (19.2) 0.5
  Females  62.8 (12.6) 57.1 (9.2) 0.05
Body mass index, mean (sD)
  Males  23.9 (3.3) 24.8 (5.6) 0.5
  Females  23.6 (5.1) 21.1 (3.0) 0.05
ice application
  no (%) 43 (63.2) 39 (59.1) 0.6
  Yes (%) 25 (36.8) 27 (40.9) 0.6
enrollment delay: mean (hours) 17.3 19.9 0.4
injured ankle periarticular edema (mm) 
  Mean (sD) 254 (27) 253 (29)
  Median (minimum-maximum) 256 (150–300) 260 (127–302) 0.9
VAs self-evaluation (patient)
  Mean (sD) 66.9 (10.6) 70.0 (11.8)
  Median (minimum-maximum) 66.0 (50–92) 67.5 (50–100) 0.2
Pain at rest (clinician)
  none/low/moderate/high 10/32/24/2 11/28/23/4 0.8
Pain on passive stretch (clinician)
  none/low/moderate/high 0/4/36/28 0/4/29/33 0.4
Pain on palpation (clinician)
  none/low/moderate/high 0/0/23/45 0/2/21/43 0.7
single foot leaning (patient)
  Okay without pain/okay with pain/impossible  4/52/12 6/44/16 0.5
Note: aFisher’s exact test of heterogeneity for dichotomous variables and Wilcoxon nonparametric test for quantitative variables.
Abbreviations: DeTP, diclofenac epolamine topical patch; n, number of patients; sD, standard deviation; VAs, visual analog scale.
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Figure 1 change in spontaneous pain, as measured by VAs, median percent change from baseline. 
Note: *Denotes statistically significant difference.
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analog score (expressed as percent of baseline) and defined 
as (minimally) a 30% reduction in pain, the success rate was 
significantly higher in the DETP group from four hours after 
the first application (36.8% DETP versus 16.7% placebo, 
P = 0.01, n = 134), and remained significant for seven of the 
10 measures until day 2 at the 8 pm time point.
The secondary efficacy measures of pain at rest, on pas-
sive stretch, on palpation, and possibility of foot leaning 
were similar between the two groups on day 0. In contrast, 
on day 3 and day 7, the DETP group showed a favorable 
response in analgesic effect that was statistically significant 
compared with the placebo group in each of the four analgesic 
efficacy measures (Table 2). Perimalleolar edema values did 
not show any significant difference between the treatment 
groups throughout the study.
Tolerability
The DETP and placebo patch were equally well tolerated on 
both day 3 and day 7, indicating consistent tolerance over 
time. No statistically significant difference was observed 
Table 2 Analgesic effect results
DETP 
(n = 68)
Placebo 
(n = 66)
P value
Pain at rest
  Day 0
  none/low/moderate/high  10/32/24/2 11/28/23/4 0.8
  Day 3
  none/low/moderate/high  49/18/1/0 33/25/8/0 0.002*
  Day 7
  none/low/moderate/high  60/8/0/0 41/19/6/0 0.001*
Pain on passive stretch
  Day 0
  none/low/moderate/high  0/4/36/28 0/4/29/33 0.4
  Day 3
  none/low/moderate/high  12/34/20/2 4/26/30/6 0.003*
  Day 7
  none/low/moderate/high  30/29/7/2 17/22/23/4 0.001*
Pain on palpation (%)
  Day 0
  none/low/moderate/high  0/0/23/45 0/2/21/43 0.7
  Day 3
  none/low/moderate/high  7/28/25/8 2/19/29/16 0.007*
  Day 7
  none/low/moderate/high  20/33/12/3 8/25/20/13 0.001*
Possibility of single foot leaning 
  Day 0
  Okay without pain/okay with pain/impossible  4/52/12 6/44/16 0.7
  Day 3
  Okay without pain/okay with pain/impossible 36/31/1 23/37/6 0.002*
  Day 7
  Okay without pain/okay with pain/impossible 56/11/1 37/28/1 0.001*
Note: *Denotes statistically significant difference.
Abbreviations: DeTP, diclofenac epolamine topical patch; n, number of patients.
between the DETP and placebo with either patient or 
physician assessment of tolerability on day 3 or day 7. 
The overall incidence of adverse events was comparable 
between the DETP and placebo groups. Two (3%) patients 
in the DETP and three (4.5%) patients in the placebo group 
reported an adverse event (Table 3). In both groups, adverse 
events were of mild to moderate severity and generally 
involved the skin.
Discussion
The purpose of this study was to assess the analgesic   efficacy 
of the DETP in acute ankle injury. It is apparent from the 
  efficacy data presented in this study that patients treated 
with the DETP experienced a significantly greater reduction 
in pain associated with their ankle injury, determined from 
visual analog scale scores, beginning four hours after the 
first patch application and lasting (except for a single time 
point) for the remainder of the seven-day treatment period. 
In addition, patients in the DETP treatment group experi-
enced reduced pain at rest, on passive stretch,   palpitation, Journal of Pain Research 2011:4 submit your manuscript | www.dovepress.com
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and the possibility of single foot leaning on day 3 and day 7. 
The   demonstrated benefits of topical therapy suggest that 
the origins of ankle pain in this case were primarily local. 
For patients who do not respond to local therapy, distant 
trigger points or other remote origins of pain should be 
considered.
No gastrointestinal-related adverse events were reported 
in this study. Analyses of safety data from this study are 
consistent with prior experience, with only five patients 
reporting adverse events of mild to moderate severity 
(four involving skin), and most of the patients in either 
treatment group having good/excellent product tolerability 
as judged by both the patient and investigator.8 An acknowl-
edged shortcoming of this trial is that the comparison with 
placebo, which facilitated identification of treatment-related 
adverse events, precluded the use of an active analgesic 
comparator. Additional studies should include comparison 
with other active analgesics.
By comparison, in both seven-day and 14-day studies 
involving the DETP for the treatment of acute pain, the 
incidence of adverse events related to the gastrointestinal 
system was similar for both the DETP-treated and placebo-
treated patients (0%–10%).8–10 In contrast, studies comparing 
celecoxib with naproxen or ibuprofen for the management 
of acute pain reported gastrointestinal-related adverse events 
in up to 20% of patients in the celecoxib group and 25% of 
patients in the naproxen group.12,13
Additional topical products approved in the US at this 
time include the lidocaine patch 5%, diclofenac sodium 
topical gel 1%, and diclofenac sodium topical solution 1.5%. 
Significant improvements compared with baseline were seen 
for the lidocaine patch in several studies of osteoarthritis and 
low back pain.14–16 Because all of these studies were open 
label, the results should be interpreted with caution. The 
diclofenac sodium gel 1% is a prescribed topical gel that 
can be applied directly for osteoarthritis pain of the knee 
and hand, producing efficacious pain reduction.17,18 However, 
a study comparing diclofenac gel and a ketoprofen patch 
in sports-related soft tissue injuries revealed that patients 
preferred the patch application to the gel despite equivalent 
pain reduction.19
Conclusion
This study assessed the superior analgesic efficacy of the 
DETP compared with placebo in minor sports injuries with 
a four-hour onset, while maintaining superior pain relief 
for the treatment duration. The DETP affords   localized 
NSAID treatment, thereby minimizing systemic drug 
exposure. Therefore, the DETP has an important role as 
an alternative to traditional oral NSAIDs in the treatment 
of these injuries, without the adverse event profile of the 
oral agents.
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